-
Product Insights
NewNet Present Value Model: GlycoMimetics Inc’s Uproleselan sodium
Empower your strategies with our Net Present Value Model: GlycoMimetics Inc's Uproleselan sodium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Sickle Cell Disease With Vaso-Occlusive Crisis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sickle Cell Disease With Vaso-Occlusive Crisis - Drugs In Development, 2023’, provides an overview of the Sickle Cell Disease With Vaso-Occlusive Crisis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sickle Cell Disease With Vaso-Occlusive Crisis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Acquired (Autoimmune) Hemolytic Anemia - Drugs In Development, 2023’, provides an overview of the Acquired (Autoimmune) Hemolytic Anemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acquired (Autoimmune) Hemolytic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Sickle Cell Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Sickle Cell Disease - Drugs In Development, 2023’, provides an overview of the Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GMI-1687 in Sickle Cell Disease With Vaso-Occlusive Crisis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GMI-1687 in Sickle Cell Disease With Vaso-Occlusive Crisis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GMI-1687 in Sickle Cell Disease With Vaso-Occlusive Crisis...
-
Product Insights
NewNet Present Value Model: Sangamo Therapeutics Inc’s Isaralgagene Civaparvovec
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Sector Analysis
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Acute Myeloid Leukemia (AML) Market Report Overview The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. Steady growth is anticipated at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The AML market research report offers an overview of AML, including epidemiology, symptoms, diagnosis,...
-
Company Profile
GlycoMimetics Inc – Company Profile
GlycoMimetics Inc (GlycoMimetics) is a clinical-stage biotechnology company that discovers and develops small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s lead pipeline product, uproleselan, is being developed for the treatment of relapsed/refractory acute myeloid leukemia (AML) in adults. GlycoMimetics designs galectin inhibitors for advancing treatment options for various diseases. The company designs and tests viral and bacterial entry inhibitors for dendritic cell receptors. The company uses proprietary glycobiology technology to develop treatments for diseases. It...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...